These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12008932)

  • 21. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T; Marquart JA; Marx PF; Meijers JC
    J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboxypeptidase N: a pleiotropic regulator of inflammation.
    Matthews KW; Mueller-Ortiz SL; Wetsel RA
    Mol Immunol; 2004 Jan; 40(11):785-93. PubMed ID: 14687935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CPR-Total (TAFI and activated TAFI) levels in plasma/serum of hemophiliacs.
    Guo X; Okada N; Okada H
    Microbiol Immunol; 2000; 44(1):77-8. PubMed ID: 10711603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basic carboxypeptidases of blood: significance for coagulology].
    Timofeev АV
    Biomed Khim; 2016; 62(2):141-9. PubMed ID: 27143370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets.
    Du XY; Zabel BA; Myles T; Allen SJ; Handel TM; Lee PP; Butcher EC; Leung LL
    J Biol Chem; 2009 Jan; 284(2):751-8. PubMed ID: 19010784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor.
    Plug T; Kramer G; Meijers JC
    J Thromb Haemost; 2014 Oct; 12(10):1717-25. PubMed ID: 25066897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase.
    Fogg DK; Bridges DE; Cheung KK; Kassam G; Filipenko NR; Choi KS; Fitzpatrick SL; Nesheim M; Waisman DM
    Biochemistry; 2002 Apr; 41(15):4953-61. PubMed ID: 11939791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins.
    Tan F; Jackman H; Skidgel RA; Zsigmond EK; Erdös EG
    Anesthesiology; 1989 Feb; 70(2):267-75. PubMed ID: 2913861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
    Leung LL; Nishimura T; Myles T
    Adv Exp Med Biol; 2008; 632():61-9. PubMed ID: 19025114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.
    Leung LLK; Morser J
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29883024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
    Wu C; Kim PY; Swystun LL; Liaw PC; Weitz JI
    J Thromb Haemost; 2016 Feb; 14(2):366-74. PubMed ID: 26663133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice.
    Asai S; Kimbara N; Tada T; Imai M; Campbell W; Okada H; Okada N
    Biol Pharm Bull; 2010; 33(7):1256-9. PubMed ID: 20606325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin.
    Tawara S; Sakai T; Matsuzaki O
    Thromb Res; 2016 Nov; 147():72-79. PubMed ID: 27693845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator.
    Schenk-Braat EA; Morser J; Rijken DC
    Eur J Biochem; 2001 Nov; 268(21):5562-9. PubMed ID: 11683879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.
    Huey R; Bloor CM; Kawahara MS; Hugli TE
    Am J Pathol; 1983 Jul; 112(1):48-60. PubMed ID: 6859228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.
    Hosaka Y; Takahashi Y; Ishii H
    Thromb Haemost; 1998 Feb; 79(2):371-7. PubMed ID: 9493593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational structure-based design of a novel carboxypeptidase R inhibitor.
    Lazoura E; Campbell W; Yamaguchi Y; Kato K; Okada N; Okada H
    Chem Biol; 2002 Oct; 9(10):1129-39. PubMed ID: 12401497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
    Islam I; Bryant J; May K; Mohan R; Yuan S; Kent L; Morser J; Zhao L; Vergona R; White K; Adler M; Whitlow M; Buckman BO
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1349-54. PubMed ID: 17189688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Marx PF; Mosnier LO; Meijers JC
    Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.